NASDAQ : COCP
Cocrystal Pharma, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.98 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 18.88M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 19.17M |
| Enterprise Value | 18.34M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 19.26M |
| Shares Outstanding | 19.26M |
| Shares Change (YoY) | +28.73% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 38.18% |
| Owned by Institutions (%) | 5.79% |
| Float | 11.91M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 58.08 |
| Forward PS | n/a |
| PB Ratio | 13.14 |
| P/TBV Ratio | 18.36 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 55.57 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.24 |
| Quick Ratio | 1.11 |
| Debt / Equity | 1.28 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -311.68% |
| Return on Assets (ROA) | -96.07% |
| Return on Invested Capital (ROIC) | -134.79% |
| Return on Capital Employed (ROCE) | -497.29% |
| Weighted Average Cost of Capital (WACC) | 11.59% |
| Revenue Per Employee | $33,000 |
| Profits Per Employee | -$993,800 |
| Employee Count | 10 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.48 |
| 52-Week Price Change | -7.01% |
| 50-Day Moving Average | 1.10 |
| 200-Day Moving Average | 1.10 |
| Relative Strength Index (RSI) | 43.44 |
| Average Volume (20 Days) | 36,515 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 179,193 |
| Short Previous Month | 175,246 |
| Short % of Shares Out | 0.93% |
| Short % of Float | 1.50% |
| Short Ratio (days to cover) | 3.97 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 330,000 |
| Gross Profit | -5.76M |
| Operating Income | -10.11M |
| Pretax Income | -9.94M |
| Net Income | -9.94M |
| EBITDA | -10.06M |
| EBIT | -10.11M |
| Loss Per Share | -$0.76 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 2.17M |
| Total Debt | 1.34M |
| Net Cash | 828,000 |
| Net Cash Per Share | $0.04 |
| Equity (Book Value) | 1.04M |
| Book Value Per Share | 0.08 |
| Working Capital | 620,000 |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -7.95M |
| Capital Expenditures | -12,000 |
| Depreciation & Amortization | 50,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -7.97M |
| FCF Per Share | -$0.41 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -3,063.64% |
| Pretax Margin | -3,011.52% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -28.73% |
| Shareholder Yield | -28.73% |
| Earnings Yield | -76.26% |
| FCF Yield | -41.56% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $8.00 |
| Price Target Difference | 704.02% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Oct 11, 2022 |
| Split Type | Reverse |
| Split Ratio | 1:12 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -109.08 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |